Dr. David P. Roberson

David Roberson is a pain neuroscientist and CEO of Blackbox Bio, a company he founded in 2021 with Clifford Woolf to address the need for automated, high-throughput measures of preclinical rodent behavior. He leads an active research program at Blackbox characterizing rodent behavioral phenotypes and their human correlates. His other research interest is exploring the application of psychedelics for treatment of chronic pain and central sensitization. David received his PhD from Harvard University and completed his postdoctoral training at Boston Children’s Hospital under Dr. Woolf.